Depression is a complex mental health disorder that affects emotional, cognitive, and physical functioning, with symptoms including persistent sadness, anhedonia, and diminished motivation. While traditional explanations have emphasized serotonin and norepinephrine imbalances, growing evidence highlights the critical role of dopamine in the onset and progression of depressive symptoms. This paper explores the neurobiological underpinnings of depression through the lens of dopaminergic dysfunction. It examines how disruptions in dopamine signaling—particularly in the mesolimbic and mesocortical pathways—contribute to key symptoms such as anhedonia, cognitive deficits, and psychomotor slowing. Neuroimaging and optogenetic studies reveal reduced dopaminergic activity in reward-related brain regions and stress-linked shifts in D1 and D2 receptor function. The paper also evaluates current dopamine-targeted treatments, including pharmacological approaches like bupropion and pramipexole, and brain stimulation therapies such as Deep Brain Stimulation and Electroconvulsive Therapy. While these treatments show promise, their efficacy is often limited by side effects, high costs, and variability in individual response. By synthesizing recent findings, this research emphasizes the importance of dopamine in shaping motivation, reward processing, and emotional regulation. It argues for a shift toward multifaceted, personalized treatment strategies that go beyond serotonin-based models to address the dopaminergic roots of depression. Recognizing dopamine's critical role not only opens new paths for more effective treatment, but also reframes depression as a neurobiological disorder—paving the way for earlier intervention, more targeted care, and a powerful step toward dismantling stigma.